These 3 Companies Reported Record Results and Raised Guidance
Abbott (ABT) reported $12.6B sales, an all-time high, and double-beat results, lifting adjusted EPS guidance. Taiwan Semiconductor (TSM) posted $40.2B sales, up 33% YoY, and raised full-year revenue growth to about 40%. Johnson & Johnson (JNJ) had $25.3B sales, a quarterly record, and increased FY sales and adjusted EPS guidance.
How this was made
The 30-second read
Why it matters
Each company is described as delivering a beat and lifting adjusted EPS or revenue guidance, implying traders may reprice near-term estimates and maintain momentum in the immediate post-earnings window.
Market read
Guidance increases tied to record quarterly sales are the actionable catalysts for ABT, TSM, and JNJ in the near term.
What to watch
The article does not discuss margin trajectory, cash flow, or specific risks behind guidance, which can be the real driver of follow-through after the initial beat-and-raise reaction.
Background
A multi-company Q2 earnings docket is underway, and this piece highlights three large-cap names that reported record results and raised guidance.
Ticker impact
Abbott reported a double-beat quarter and lifted adjusted EPS guidance, with sales at an all-time high of $12.6B.
Moderately positive bias for the next few sessions as traders reprice forward EPS.
The article cites both earnings beat and explicit adjusted EPS guidance increase, which typically drives follow-through if not already fully priced.
Taiwan Semiconductor posted record $40.2B sales (+33% YoY) and raised full-year revenue growth forecast to about 40%.
Potential for continued relative strength versus AI-exposed peers, though volatility may persist.
The text includes both a quarterly record and a specific full-year forecast increase, which is a concrete re-rating catalyst.
Johnson & Johnson delivered a new quarterly sales record of $25.3B and increased current fiscal-year sales and adjusted EPS guidance.
Mild-to-moderate positive drift as the market validates the raised guidance path.
The article provides explicit guidance increases and a stated 2026 revenue target milestone, supporting estimate revisions.
Market effects
Positive read-through for healthcare and semis earnings expectations, potentially stabilizing sentiment for AI-adjacent semiconductor demand.
Limited direct regional spillover beyond semis sentiment tied to Taiwan-based supply chain expectations.
Supports global risk appetite via large-cap earnings strength, especially in semiconductors and defensive healthcare.
Counterpoint
Record quarters and guidance raises may already be partially priced, so upside could fade if margins, demand durability, or AI capex timing disappoint later.
Key entities
- companyAbbott Laboratories
Reported record $12.6B sales, double-beat results, and lifted adjusted EPS guidance.
- companyTaiwan Semiconductor Manufacturing Company
Reported record $40.2B sales (+33% YoY) and raised full-year revenue growth forecast to about 40%.
- companyJohnson & Johnson
Reported record $25.3B quarterly sales and increased fiscal-year sales and adjusted EPS guidance.
%252FSemiconductor%252520by%252520Gorodenkoff%252520via%252520Shutterstock.jpg&w=3840&q=75)